These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11049889)

  • 1. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations.
    Klein SM; Slaughter TF; Vail PT; Ginsberg B; El-Moalem HE; Alexander R; D'Ercole F; Greengrass RA; Perumal TT; Welsby I; Gan TJ
    Anesth Analg; 2000 Nov; 91(5):1091-5. PubMed ID: 11049889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery.
    Tekkesin N; Tekkesin M; Kaso G
    Anatol J Cardiol; 2015 Nov; 15(11):932-7. PubMed ID: 26574762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
    Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
    Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
    Douketis JD; Kinnon K; Crowther MA
    Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit.
    White H; Sosnowski K; Bird R; Jones M; Solano C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):304-10. PubMed ID: 22473047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
    Brophy DF; Martin EJ; Gehr TW; Carr ME
    Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
    Louis SG; Van PY; Riha GM; Barton JS; Kunio NR; Underwood SJ; Differding JA; Rick E; Ginzburg E; Schreiber MA
    J Trauma Acute Care Surg; 2014 Apr; 76(4):937-42; discussion 942-3. PubMed ID: 24662855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does prior administration of enoxaparin influence the effects of levobupivacaine on blood clotting? Assessment using the Thrombelastograph.
    Leonard SA; Lydon A; Walsh M; Fleming C; Boylan J; Shorten GD
    Br J Anaesth; 2001 Jun; 86(6):808-13. PubMed ID: 11573588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
    Konstantinidis K; Gerasimidis T; Verdy E; Elalamy I; Samama MM; Gerotziafas GT
    Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients.
    Carroll RC; Craft RM; Whitaker GL; Snider CC; Kirby RK; Elder RF; Hennessey MD
    Thromb Res; 2007; 120(3):367-70. PubMed ID: 17150243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
    Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
    J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose?
    Dhillon NK; Smith EJT; Gillette E; Mason R; Barmparas G; Gewertz BL; Ley EJ
    Int J Surg; 2018 Mar; 51():128-132. PubMed ID: 29367044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
    Bösch J; Rugg C; Schäfer V; Lichtenberger P; Staier N; Treichl B; Rajsic S; Peer A; Schobersberger W; Fries D; Bachler M
    Semin Thromb Hemost; 2022 Oct; 48(7):850-857. PubMed ID: 36174602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboelastometry versus free-oscillation rheometry and enoxaparin versus tinzaparin: an in-vitro study comparing two viscoelastic haemostatic tests' dose-responses to two low molecular weight heparins at the time of withdrawing epidural catheters from ten patients after major surgery.
    Thomas O; Larsson A; Tynngård N; Schött U
    BMC Anesthesiol; 2015 Nov; 15():170. PubMed ID: 26603039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboelastography (TEG®) demonstrates that tinzaparin 4500 international units has no detectable anticoagulant activity after caesarean section.
    Griffiths S; Woo C; Mansoubi V; Riccoboni A; Sabharwal A; Napier S; Columb M; Laffan M; Stocks G
    Int J Obstet Anesth; 2017 Feb; 29():50-56. PubMed ID: 27887785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.